Opus Genetics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Opus Genetics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 64%
Sales fell 64% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-64% / +3%In 3 years sales changed by -64% while total assets changed by +3%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
+14%Cash, after subtracting all debt, equals 14% of its market value (net cash).
Higher than 55% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Opus Genetics, Inc. made a loss over the last year. Opus Genetics, Inc. owes $1.14 for every $1 it owns. Opus Genetics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossOpus Genetics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-24.47Opus Genetics, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$318 MThe total market value of all of Opus Genetics, Inc.'s shares at today's price (share price × number of shares), smaller than 51% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
NegativeOpus Genetics, Inc.'s net worth is negative ($13 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Return on equity (ROE)
-4796.5%Opus Genetics, Inc. lost 4796.5% of its shareholders' money over the last year, lower than almost all Healthcare companies in United States.
Owes vs Owns
1.14×Opus Genetics, Inc. owes $1.14 for every $1 it owns, so it owes more than it owns, higher than 90% of Healthcare companies in United States.
Dividend yield
NoneOpus Genetics, Inc. does not currently pay a dividend.
Revenue growth
+29%Revenue rose 29% in the year to Dec 2025, and shrank 29% a year on average over 3 years.
Profit growth
LossOpus Genetics, Inc. made a loss in each of the last two years.
Profit margin
-349.3%Opus Genetics, Inc. lost $349 for every $100 of revenue.
Interest cover
Not coveredOpus Genetics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashOpus Genetics, Inc. held $44 M more cash than debt (net cash) at Dec 2025.
Questions
What is Opus Genetics, Inc.'s return on equity?
Opus Genetics, Inc. lost 4796.5% of its shareholders' money over the last year, lower than almost all Healthcare companies in United States.
How much does Opus Genetics, Inc. owe compared with what it owns?
Opus Genetics, Inc. owes $1.14 for every $1 it owns, so it owes more than it owns, higher than 90% of Healthcare companies in United States.
Does Opus Genetics, Inc. pay a dividend?
No. Opus Genetics, Inc. does not currently pay a dividend.
Is Opus Genetics, Inc.'s revenue growing?
Revenue rose 29% in the year to Dec 2025, and shrank 29% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.